Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Ovarian Neoplasms

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 13 articles:
HTML format



Single Articles


    October 2022
  1. WANG Y, Han A, Chen E, Singh RK, et al
    [Corrigendum] The cranberry flavonoids PAC DP9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


  2. LI R, Wang Y, Xu Y, He X, et al
    [Retracted] Silencing the long noncoding RNA, TINCR, a molecular sponge of miR335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


  3. BJERSAND K, Blom K, Poromaa IS, Stalberg K, et al
    Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


  4. KIM SH, Baek KH
    Ovarian tumor deubiquitinase 6A regulates cell proliferation via deubiquitination of nucleolin and caspase7.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    July 2022
  5. FEDIER A, Maggi N, Tozzi A, Disler M, et al
    Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    May 2022
  6. ZHANG R, Roque DM, Reader J, Lin J, et al
    Combined inhibition of IL6 and IL8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


  7. LAVORO A, Scalisi A, Candido S, Zanghi GN, et al
    Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    March 2022
  8. SINGH T, Neal A, Dibernardo G, Raheseparian N, et al
    Efficacy of birinapant in combination with carboplatin in targeting platinumresistant epithelial ovarian cancers.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    July 2021
  9. CHAUVIN M, Garambois V, Choblet S, Colombo PE, et al
    Anti-Mullerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
    Int J Oncol. 2021;59.
    PubMed     Abstract available


  10. FALZONE L, Scandurra G, Lombardo V, Gattuso G, et al
    A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).
    Int J Oncol. 2021;59.
    PubMed     Abstract available


    May 2021
  11. THONGCHOT S, Jamjuntra P, Therasakvichya S, Warnnissorn M, et al
    Interleukin8 released by cancerassociated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells.
    Int J Oncol. 2021;58.
    PubMed     Abstract available


    September 2020
  12. LIU J, Liu D, Liu JJ, Zhao C, et al
    [Corrigendum] Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells.
    Int J Oncol. 2020 Sep 28. doi: 10.3892/ijo.2020.5129.
    PubMed     Abstract available


    April 2020
  13. GUO F, Zhang K, Li M, Cui L, et al
    miR5083p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7.
    Int J Oncol. 2020 Apr 27. doi: 10.3892/ijo.2020.5055.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: